COMP <GO>
MOH vs MRK // PIOTROSKI F-SCORE QUALITY
Molina Healthcare Inc (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: MOH 3
— MRK 12
▲ PIOTROSKI F-SCORE QUALITY LEADER: MRK
LAST: $204.78 (+2.93%) • MKT CAP: $10.39B
piotroski-score
4/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MOH VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MOH | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 13.10% | 74.80% | -61.70 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.20% | 20.70% | -3.50 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.4x | 15.3x | -3.90 | MOH | /valuation <GO> |
| Free Cash Flow Yield | -6.12% | 3.42% | -9.54 | MRK | /fcf-yield <GO> |
| Operating Margin | 1.70% | 34.30% | -32.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | 1.00% | 28.10% | -27.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 11.70% | 1.30% | +10.40 | MOH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.34 | 5.19 | -0.85 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.60% | +0.10 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.5 | 56.9 | -5.34 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 0.92 | +0.02 | MOH | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.5x | 18.4x | +2.10 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.39B | $361.02B | -$350.64B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MOH REV | MRK REV | MOH GROSS % | MRK GROSS % | MOH FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $45.43B | $65.01B | 13.1% | 74.8% | -$636.0M | $12.36B |
| FY 2024 | $40.65B | $64.17B | 15.3% | 76.3% | $544.0M | $18.10B |
| FY 2023 | $34.07B | $60.12B | 44.0% | 44.0% | $128.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MOH // BETA 0.94
MRK // BETA 0.92